Phase I/II Clinical Trial in Chronic Lymphocytic Leukemia to Evaluate Combination Therapy with Biothera’s Imprime PGG

Published: Mar 14, 2011

EAGAN, Minn.--(BUSINESS WIRE)--Patients with earlier stage high-risk Chronic Lymphocytic Leukemia (CLL) recently began receiving a new combination treatment in a Phase I/II clinical trial that researchers believe could result in a more effective therapy for this disease, Biothera announced today.

Back to news